Intel stock today: INTC dips into 2026 as Nvidia’s $5B stake keeps focus on what’s nextNEW YORK, January 1, 2026, 10:13 ET — Market closed

Intel stock today: INTC dips into 2026 as Nvidia’s $5B stake keeps focus on what’s nextNEW YORK, January 1, 2026, 10:13 ET — Market closed

  • Intel shares last closed down about 1% at $36.90 in the final U.S. session of 2025.
  • Nvidia has completed a $5 billion private placement purchase of Intel stock, an SEC filing showed. Investing
  • Traders are watching chip-sector sentiment and late-January earnings timing as markets reopen Friday. Nasdaq

Intel Corp (INTC.O) shares closed down about 1% at $36.90 on Wednesday, the final trading session of 2025, with U.S. markets shut on Thursday for New Year’s Day. Nasdaq

The move matters because Intel heads into 2026 after a sharp run-up in 2025, leaving less room for missteps as investors look for proof that funding and partnerships can translate into results. Investing

That scrutiny has sharpened after Nvidia’s $5 billion investment, which adds cash but also increases Intel’s share count — a dilution risk for existing holders if profits don’t rise fast enough. Investing

Intel said in an SEC filing it completed the sale of 214,776,632 shares to Nvidia (NVDA.O) for $5.0 billion in cash, at $23.28 per share. The company said the deal was done as a private placement, meaning the shares were sold outside the public market. Investing

U.S. antitrust agencies cleared Nvidia’s investment in Intel earlier in December, according to a Federal Trade Commission notice cited by Reuters. Reuters

Intel’s late-December trading has also tracked a softer tone in equities into year-end. The S&P 500 fell 0.74% and the Nasdaq Composite lost 0.76% in the final session of 2025, Reuters reported. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking when liquidity is low. Reuters

Chip stocks broadly weakened alongside the market. The iShares Semiconductor ETF fell 1.2%, while the Nasdaq-100 tracking QQQ slipped 0.8%. Nvidia and Advanced Micro Devices (AMD.O) each eased about 0.5%, while U.S.-listed shares of Taiwan Semiconductor Manufacturing rose 1.4%.

Intel traded between $36.82 and $38.01 on Wednesday, according to market data. The stock ended 2025 about 15% below its 52-week high of $44.02 reached on Dec. 3, MarketWatch data showed. MarketWatch

For investors, the next test is whether Intel can show momentum in core PC and data-center chips while advancing its bid to rebuild manufacturing competitiveness — a pressure point as rivals such as AMD and Taiwan’s TSMC set the pace in key markets. Reuters

Before the next session, the focus shifts to Friday’s reopening after the holiday closure. Year-start flows often bring sharp moves in large-cap tech and semiconductors, especially after a year-end slide. Nasdaq

Earnings are the next major scheduled catalyst. Yahoo Finance’s earnings calendar lists Intel for Jan. 29 after the close, while Nasdaq’s earnings page also shows Jan. 29 as an estimate based on prior reporting patterns. Yahoo Finance

From a trading standpoint, Intel’s near-term levels are straightforward: bulls will want to see the shares reclaim the $38 area from Wednesday’s range, while bears will watch whether support around $37 holds as markets resume.

Stock Market Today

  • FDA Extends FILSPARI Review to April 2026: Impact on Travere Therapeutics' Stock Story
    January 22, 2026, 12:35 AM EST. Travere Therapeutics (TVTX) faces an extended FDA review for FILSPARI in focal segmental glomerulosclerosis (FSGS), a rare kidney disease with no current approved treatments. The revised Prescription Drug User Fee Act (PDUFA) action date is April 13, 2026, pushing back a key regulatory milestone. This delay does not stem from safety issues but reflects the FDA's request for additional data to better characterize clinical benefits. The prolonged timeline dampens near-term momentum, weighing on TVTX shares and increasing regulatory timing risk. Market expectations are now adjusting, amid a wide range of fair value estimates from $19 to over $115 per share. Investors should monitor the evolving landscape closely, balancing potential long-term gains from FILSPARI's approval against interim financial pressures from ongoing losses and cash burn.
Nike stock today: NKE rises after CEO Elliott Hill buys $1 million of shares
Previous Story

Nike stock today: NKE rises after CEO Elliott Hill buys $1 million of shares

Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus
Next Story

Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus

Go toTop